Status:
COMPLETED
First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory
Lead Sponsor:
Nicola Irwin
Conditions:
Respiratory Syncytial Viral (RSV) Infection
Respiratory Syncytial Virus Hospitalizations
Eligibility:
All Genders
Up to 2 years
Brief Summary
The goal of this observational study is to explore the impact of a new prevention medicine (nirsevimab) on the burden of Respiratory Syncytial Virus (RSV) disease in children under 2 years of age. The...
Detailed Description
RSV infection is the leading cause for hospitalisation in young children. Treatment of RSV is primarily supportive, and includes supplemental oxygen therapy, ventilatory support, and fluid management....
Eligibility Criteria
Inclusion
- child aged less than 2 years
- laboratory confirmed RSV
Exclusion
- n/a
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
2355 Patients enrolled
Trial Details
Trial ID
NCT07177508
Start Date
December 1 2024
End Date
July 30 2025
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Canberra Hospital
Garran, Australian Capital Territory, Australia, 2605